Drug Profile
Research programme: autoimmune and inflammatory disorders therapeutics - FF Pharmaceuticals
Alternative Names: FFP 106; PG 120; PG 140Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator PanGenetics BV
- Developer FF Pharma; PanGenetics BV
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors; CD86 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Digestive system disorders; Inflammation; Transplant rejection
- Discontinued Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Digestive system disorders in Netherlands (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in Netherlands
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Netherlands